Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
August 17, 2022 06:21 AM EDTUpdated August 19, 04:07 AM
R&D

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Amber Tong

John Carroll

Editor & Founder

Sanofi is of­fi­cial­ly giv­ing up on its oral SERD.

The French drug­mak­er put out word Wednes­day morn­ing that it will

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times